Pompe Disease
Conditions
Keywords
Pompe Disease, Infusion Associated Reaction, Immune-modulation regimen
Brief summary
Hypothesis: the effectiveness of treatment of Pompe Disease with rhGAA enzyme replacement therapy (ERT) is limited at least in part because patients develop antibodies against the provided rhGAA enzyme. Treatment with immunomodulatory drugs may dampen or eliminate the anti-rhGAA immune response in patients receiving ERT, thereby allowing for greater ERT efficacy. Studying the immune response to rhGAA may provide valuable insight into the role of the immune system in the effectiveness of ERT for Pompe Disease.
Detailed description
The purpose of this research study is to determine the effect(s) of medications that alter the immune system on anti-rhGAA immune response in Pompe patients receiving rhGAA enzyme replacement therapy (ERT). The investigators would also like to determine whether treating Pompe Disease with medications that affect the immune system has any effects on the overall health or disease progression of Pompe. Subjects will be patients between the ages of 0 months and 65 years who have been diagnosed with Pompe Disease, confirmed by mutational analysis and/or GAA enzyme activity assay. Subjects will be eligible regardless of whether they have begun enzyme replacement therapy prior to enrollment. All Subjects will receive enzyme replacement therapy as standard of care during the course of the Study, although they may not have begun ERT treatment at the time of enrollment. In addition to ERT, subjects may receive an immunomodulatory regimen as part of their standard of care; this may include rituximab, sirolimus, methotrexate, IVIg or other immunomodulatory agents such as pharmacological chaperone N-butyldeoxynojirimycin (NB-DNJ), alone or in combination, at the discretion of their caregiver(s).
Interventions
DRUGRituximab
Clinically prescribed immune modulation regimen dosage determined by local medical provider.
DRUGMiglustat
Clinically prescribed immune modulation regimen dosage determined by local medical provider.
Sponsors
University of Florida
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
No minimum to 65 Years
Healthy volunteers
No
Inclusion criteria
* patients between the ages of 0 months and 65 years * diagnosed with early-onset Pompe Disease, confirmed by mutational analysis and/or GAA enzyme assay * eligible regardless of whether they have begun enzyme replacement therapy prior to enrollment * all subjects will receive ERT as standard of care during the course of the study, although they may not have begun ERT treatment at the time of enrollment * subjects may receive an immunomodulatory regimen as part of their standard of care; this may include rituximab, sirolimus, methotrexate, Gamunex, Hizentra, Zavesca or other immunomodulatory agents, alone or in combination, at the discretion of their caregiver(s)
Exclusion criteria
* subject is unable to meet the study requirements * subjects medical condition contraindicates participation or Study Investigators feel that participation is otherwise not in the subject's best interest * subject does not receive ERT treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Anti-rh GAA antibody titers | 52 weeks | Antibody titer for anti-rh-GAA will be evaluated at baseline and every 4-8 weeks for 52 weeks of participation in the primary study. For subjects who continue participation in the extension study (\>52 weeks - 5 years), anti-rh-GAA antibody titers will be evaluated every 12 - 24 weeks. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| B-lymphocyte antigen (CD20) level | 52 weeks | Reports from clinical lab: B-lymphocyte antigen (CD20) will be added to the study record when available every 4-12 weeks during the primary study and every 12 weeks for subjects who participate in the extension study (\>52 weeks - 6 years) |
Countries
United States
Outcome results
None listed